Literature analysis of lung toxicity related to cyclin-dependent kinase 4/6 inhibitors
- VernacularTitle:周期蛋白依赖性激酶4/6抑制剂相关肺毒性的文献分析
- Author:
Jun ZHAO
1
;
Guangwei LIU
1
;
Yuyan LIN
2
;
Xiaolei ZHANG
1
;
Beibei NI
1
Author Information
1. Dept. of Pharmacy，the Affiliated Hospital of Qingdao University，Shandong Qingdao 266003，China
2. Dept. of Pharmacy，Shenzhen Hospital of Guangzhou University of Chinese Medicine （Futian），Guangdong Shenzhen 518000，China
- Publication Type:Journal Article
- Keywords:
cyclin-dependent kinase 4/6 inhibitors;
lung toxicity;
adverse drug reaction;
literature analysis
- From:
China Pharmacy
2023;34(3):355-360
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide reference for rational use of cyclin-dependent kinase 4/6 （CDK4/6） inhibitors. METHODS Retrieved from Web of Science， PubMed， SpringerLink， CNKI， Wanfang Data and VIP database， and so on， the literature about lung toxicity related to CDK4/6 inhibitors were collected and analyzed statistically with Excel 2013 software. RESULTS A total of 12 literature which met the inclusion and exclusion criteria were included； 13 patients were involved， among which 3 cases were from the United States， 3 from Japan， 2 from India， and 1 from Israel， Spain， France， Australia and Saudi Arabia respectively； all patients were female， aged between 43-89 years， of whom 8 were treated with palbocicilib， 3 with abemacilib， and 2 with ribociclib. The lung toxicity of patients after medication occurred from 1 week to 15 months； the majority of patients were hospitalized with the symptom such as difficulty breathing， chest tightness， shortness of breath， dry cough， etc. The lung toxicity mainly manifested as interstitial lung disease， eosinophilic pneumonia， mediastinal and pulmonary granulomatous reaction， drug-induced pneumonia， diffuse alveolar damage， organizing pneumonia and so on. The shortest treatment duration was 3 weeks， and the longest was 6 months. The treatment measures included drug withdrawal， intravenous use of antibiotics， intravenous use of systemic steroids， oxygen inhalation， and so on； after treatment， 8 patients improved or recovered， and 5 patients died due to deterioration. One patient developed lung toxicity again after reuse of such drugs and must stop drugs permanently. CONCLUSIONS Lung toxicity related to CDK4/6 inhibitors possibly cause mortality. It is necessary to make early judgment， stop the drug in time， and give patients systemic steroids， oxygen inhalation and other treatment measures as soon as possible.
